深圳普罗吉医药科技

Protogy is a Chinese biotechnology company specializing in the development of innovative tumor markers and diagnostic reagents. The company is best known for its Heat Shock Protein 90 alpha (Hsp90α) quantitative detection kit, which was developed in collaboration with Tsinghua University and has received NMPA approval for clinical use in lung and liver cancer screening. Protogy focuses on early cancer detection and monitoring, leveraging recombinant protein technology to provide non-invasive diagnostic solutions. The company's Hsp90α kit represents the first clinical application of this protein as a tumor marker globally. Protogy continues to expand its diagnostic portfolio to address various oncological indications, aiming to improve patient outcomes through early intervention.